Navigation Links
Study Supports Cost-Effectiveness of Medtronic's Spasticity,Treatment for Children with Cerebral Palsy

MINNEAPOLIS--(BUSINESS WIRE)--Apr 26, 2007 - A new study published in the current issue of the Journal of Child Neurology indicates that a treatment from Medtronic, Inc. (NYSE:MDT), for spasticity in children with cerebral palsy improves their quality of life and is cost-effective compared to other established cost-effective treatments. The findings of this Medtronic-sponsored study should expand access to the treatment, known as Medtronic ITB Therapy(SM) (Intrathecal Baclofen Therapy).

Cerebral palsy affects an estimated 764,000 people in the United States, according to United Cerebral Palsy, with approximately 8,000 babies and 1,200 to 1,500 preschool-age children diagnosed with the condition each year. Caused by damage to one or more areas of the developing brain, cerebral palsy is characterized by an inability to control motor function fully, particularly muscle control and coordination.

The most common form of cerebral palsy involves spasticity - tight, stiff muscles that make coordinated movement (especially of the arms and legs) difficult or uncontrollable. Up to 80 percent of children with cerebral palsy develop spasticity, which can be painful and limit functional ability for the patient, and tax the patient's family physically, emotionally, and financially.

Medtronic ITB Therapy, which uses the company's SynchroMed(R) implantable infusion system to deliver a muscle relaxant directly to the fluid-filled area surrounding the spinal cord, can effectively reduce severe spasticity with fewer side-effects than oral medication. By reducing spasticity, ITB Therapy may also improve function, quality of life, and ease of care.

Despite the treatment's well-demonstrated clinical efficacy, ITB Therapy remains underused - in large part because of concerns about the cost of the pump and the surgery to implant it.

"The cost of ITB Therapy should not prevent pediatric patients with spastici ty of cerebral origin from receiving this clinically effective treatment," explained Dr. Terence Edgar of the Medical College of Wisconsin's Department of Neurology and senior author of the study. "Specifically, we found that the projected improvement in quality of life justifies the estimated five-year treatment cost based on well-established guidelines for cost-effectiveness."

Dr. Edgar and colleagues, including a team of health economists from United BioSource Corp. in Bethesda, Md., "used mathematical modeling and computer simulation to estimate the incremental cost per quality-adjusted life-year for identical cohorts of children treated with intrathecal baclofen or alternative therapy during a five-year episode of treatment," according to the study abstract. "On average, intrathecal baclofen therapy increased the five-year cost of treatment by $49,000 relative to alternative treatment. However, this was accompanied by an average gain of 1.2 quality-adjusted life-years. The net result was an incremental cost-effectiveness ratio of $42,000 per quality-adjusted life-year, a figure well (below) the $50,000 to $100,000 range that is widely accepted as offering good value for money."

Supported by Medtronic, this analysis of ITB Therapy's cost-effectiveness is the first in the context of the U.S. healthcare system.

"Cost-effectiveness is an important consideration in today's healthcare environment," said Dr. Richard E. Kuntz, M.D., senior vice president of Medtronic, Inc., and president of the company's Neurological business. "This study supports the cost-effectiveness of Medtronic ITB Therapy, an effective treatment for severe spasticity that has the potential to restore functional ability and a better quality of life to thousands of people every year."

Medtronic ITB Therapy is indicated for the management of severe spasticity of cerebral and spinal origin, including stroke, cerebral palsy, brain injury, spinal cord injury, and multiple sc lerosis. It uses Medtronic's SynchroMed Implantable Infusion System, which consists of a programmable drug pump connected to a thin tube, or catheter, to deliver precise amounts of a muscle relaxant called Lioresal(R) Intrathecal (baclofen injection) directly to the intrathecal space - the fluid-filled area surrounding the spinal cord, the drug's site of action. By targeting the spinal cord, ITB Therapy reduces spasticity with smaller amounts of medication than would be required orally. Intrathecal infusion, which bypasses the body's blood-brain barrier, also minimizes systemic side-effects.

ITB Therapy drug side effects are usually temporary and manageable by adjusting the dose. The most common side effects include loose muscles, drowsiness, nausea/vomiting, headache, and dizziness. Abrupt discontinuation of intrathecal baclofen, regardless of the cause, can result in high fever, altered mental status, returned spasticity, and muscle rigidity, and in rare cases has been fatal. Prevention of abrupt discontinuation of intrathecal baclofen requires careful attention to programming and monitoring of the infusion system, refill scheduling and procedures, and pump alarms.

Children should be of sufficient body mass to accommodate the pump. The safety and efficacy of ITB Therapy in pediatric patients below the age of four have not been established.

More information about ITB Therapy is available online at www.spasticity.com or by calling toll-free 1-800-856-3823. Other pharmaceutical treatments for spasticity include oral and injectable medications.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 28, 2006. Actual results may differ materially from anticipated results.

Lioresal(R) is a registered trademark of Novartis Pharmaceuticals Corporation.

Contact

Medtronic, Inc.
Investor Relations:
Jeff Warren, 763-505-2696
or
Public Relations:
Joe McGrath, 763-505-0291


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Texas , April 20, 2017  Vivify Health, ... mobile devices, has been awarded a very significant patent ... via EMRs to continual care via digital health.  This ... key intellectual property and further secures Vivify,s position as ... launched in 2009, was the first company to apply ...
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
(Date:4/28/2017)... Manhattan New york (PRWEB) , ... April 28, ... ... is pleased to announce that Aditya Patel M.D. has joined the revolutionary endoscopic ... fellowship training and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt ...
(Date:4/28/2017)... Edinburg, Texas (PRWEB) , ... April 28, 2017 , ... ... a plaque in recently to the labor and delivery team at Women’s Hospital at ... generous mothers who give birth at the hospital and decide to donate. , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and elimination ... safety and minimize the cost of development. In this webinar, sponsored by Molecular ... lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , In ...
(Date:4/28/2017)... ... 28, 2017 , ... Bill Howe started his sewer and drain company in ... Howe joined the team, the Bill Howe brand was born and they began cultivating ... giving back to the San Diego community in which they worked, lived and were ...
Breaking Medicine News(10 mins):